Tim Moore, Chief Technical Officer of Allogene, is featured in this month’s issue of BioProcess International with his take on the potential of off-the-shelf allogeneic #CAR T products to revolutionize cancer care. #celltherapy #immunotherapy https://lnkd.in/ggAz2PPa
Allogene Therapeutics’ Post
More Relevant Posts
-
We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
-
We are pleased to announce activation of three community cancer centers as first sites open in our pivotal Phase 2 ALPHA3 trial evaluating cema-cel as part of 1L treatment in #LBCL. Patient screening underway at Rocky Mountain Cancer Centers (RMCC), part of the Sarah Cannon Research Institute and US Oncology Network (Colorado), Astera Cancer Care (ACC), part of the OneOncology Network (New Jersey), and Norton Healthcare. #CART #celltherapy Foresight Diagnostics. https://lnkd.in/gRCrNcE9
-
Our own Zach Roberts provides his perspective on how allogeneic CAR T products may be a solution to problems facing autologous CAR T products for patients with #CLL in the latest issue of Cell & Gene. #Immunotherapy #CART
The Path Forward for CLL is Allogeneic https://lnkd.in/euvZhyWK By Zachary J Roberts MD PhD, Executive Vice President, Research & Development, and Chief Medical Officer, Allogene Therapeutics Chronic lymphocytic leukemia (CLL) remains a disease that is managed, not one that is often cured.
-
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene: Allogene.com/Science
-
-
Thrilled to announce the initiation of our groundbreaking 1L consolidation ALPHA3 trial, which has the potential to redefine the future of CAR T and treatment of LBCL, and expand access in the community cancer setting. Foresight Diagnostics $ALLO #CART #celltherapy #immunotherapy Learn more about ALPHA3: https://lnkd.in/g_sxiYVw
-
Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. $ALLO #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: Allogene.com/Home
-
Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329: Allogene.com/Pipeline
-
Looking forward to hearing Zachary J Roberts MD PhD talk about the potential of CAR T in earlier lines of cancer treatment at the 6th Allogeneic Cell Therapies Summit on June 12. $ALLO #CART #celltherapy #immunotherapy Hanson Wade Group Learn more here: https://lnkd.in/gUxJCtSv
-
